DAILYPEPTIDE GUIDE
Approved Therapeutic

Tirzepatide

Mounjaro · Zepbound · LY3298176

Tirzepatide is an approved peptide-based therapeutic or diagnostic asset. Product-specific labels define its validated uses and risks.

Compare
EvidenceTier 1
RegulatoryApproved
SafetyKnown but Manageable Risks
Clinical phaseApproved
01

Overview

ClassDual incretin peptide agonist
Sponsor / developerEli Lilly and Company
Review statusReviewed
Record IDPEP-002
02

Plain-language guide

What it was designed or studied for

Designed and approved for specific uses that include Type 2 diabetes, Chronic weight management.

How it works, simply

It copies two gut-hormone signals that help the body respond to food, regulate blood sugar and communicate fullness to the brain.

This simplified explanation is educational context, not a treatment recommendation or a substitute for the clinical evidence below.
03

Clinical mechanism

Selectively activates GIP and GLP-1 receptors.

Mechanism plausibility is not the same as demonstrated clinical benefit.
04

Applications

  • Type 2 diabetes
  • Chronic weight management
05

Human evidence

Multiple human studies and regulatory review support at least one product-specific indication.

Tier 1
06

Preclinical evidence

Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.

MAP

Muscle & recovery profile

Each signal is scored independently from 0–5. There is no composite “best” score.

Growth relevance0/5
Preservation relevance2/5
Recovery relevance0/5
Mitochondrial support1/5
Connective tissue0/5
Human-data depth5/5
Safety confidence4/5
Evidence–hype gap1/5

Evidence classes

  • Phase 3 / randomized human evidence

What has been studied

  • Large human trials establish approved metabolic and weight-management outcomes; body-composition analyses include lean-mass change.

What is not established

  • It is not designed to build muscle, and preserving lean mass during weight loss requires broader clinical context.

Studied populations

  • Adults with type 2 diabetes
  • Adults meeting approved chronic-weight-management criteria

Major limitations

  • Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
  • Findings from one population, formulation or indication should not be generalized to another.

Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.

06

Regulatory status

Approved. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.

07

Safety

Known but Manageable Risks

  • Adverse effects vary by product and indication
  • Contraindications and interactions require label review
08

Interactions

Review the current product label and indication-specific literature for pharmacologic and absorption interactions.

09

Treatment pattern

Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.

10

Manufacturing and quality

Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.

12

Sources

  1. 01
    Primary regulatory record

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  2. 02
    Clinical trial registry

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  3. 03
    Peer-reviewed literature

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

13

Gaps and unverified claims

  • Evidence must be interpreted by indication and product label.
  • Approval does not establish safety or efficacy for off-label or compounded copies.
14

Last reviewed

August 5, 2026 · Reviewed